Oncoceutics, Inc.

Part of Chimerix, Inc.

UEI
ZKPGUP3MLBW9
CAGE
5J9A9
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
Corporate family
SAM.gov registration date
Website
oncoceutics.com
Founded
2009
Employees
1-10
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Clinical efficacy evaluation of first-in-class imipridone ONC201 in recurrent type II endometrial cancer R44CA221398 National Cancer Institute (NIH) $1,685,910
Phase i/II trial of ONC201 for the treatment of multiple myeloma IND121,496 (01/05/2015) R01FD005402 FDA Office of Acquisition and Grant Services $1,242,857
Clinical efficacy of the antitumor agent ONC201 in GBM R44CA192427 National Cancer Institute (NIH) $4,833,150

Quick answers

Is Oncoceutics, Inc. registered in SAM.gov?

Oncoceutics, Inc.'s SAM.gov registration expired on March 7, 2022.

What is Oncoceutics, Inc.'s most recent federal award?

Oncoceutics, Inc.'s most recent federal grant award is Clinical efficacy evaluation of first-in-class imipridone ONC201 in recurrent type II endometrial cancer (R44CA221398), from National Cancer Institute (NIH), on August 17, 2017.

On GovTribe

See Oncoceutics, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login